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Abstract
Background: Results from large epidemiologic studies on the association between vitamin D and gastric cancer
are controversial. Vitamin D significantly promotes apoptosis in the undifferentiated gastric cancer cell, but the
prognostic effects of its levels are unknown.
Methods: 197 gastric carcinoma patients who received treatment in the cancer centre of Sun Yat-sen University
from January 2002 to January 2006 were involved in the study. The stored blood drawn before any treatment was
assayed for 25-hydroxyvitamin D levels. The clinicopathologic data were collected to examine the prognostic
effects of vitamin D.
Results: The mean vitamin D levels of the 197 gastric patients was 49.85 ± 23.68 nmol/L, among whom 114
(57.9%) were deficient in Vitamin D(< 50 nmol/L), 67(34%) were insufficient (50-75 nmol/L) and 16(8.1%) were
sufficient (> 75 nmol/L). Clinical stage (P = 0.004) and lymph node metastasis classification (P = 0.009) were
inversely associated with vitamin D levels. The patients with high vitamin D levels group (≥ 50 nmol/L) had a
higher overall survival compared with the low vitamin D levels group (< 50 nmol/L)(P = 0.018). Multivariate analysis
indicated that vitamin D levels were an independent prognostic factor of gastric cancer (P = 0.019).
Conclusions: Vitamin D deficiency may be associated with poor prognosis in gastric cancer.
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Background
Gastric cancer is the fourth most common cancer and
the second leading cause of cancer-related deaths fol-
lowing lung carcinoma despite a worldwide decline in
both incidence and mortality since the later half of the
twentieth century [1]. Although in most Western coun-
tries the incidence lies between 10 and 15 new cases per
100,000 population per year, China, Japan and Korea
now have up to 80 new cases per 100,000 population
per year [2].
Vitamin D is a secosteroid hormone critical to skeletal
health and other biological pathways [3]. Vitamin D3 is the
natural form of vitamin D produced in skin through ultra-
violet irradiation of 7-dehydrocholesterol. It is biologically
inert and must be metabolized to 25-hydroxyvitamin D3
in the liver and then to 1,25-dihydroxyvitamin D3 (VD3)
in the kidney before functioning [4]. Earlier studies
showed that 1,25-dihydroxyvitamin D3, the physiologically
active form of vitamin D, could induce differentiation and
cell cycle arrest in a number of malignant cells, including
those in myeloid leukemia, and breast, prostate, colon,
skin and brain cancer [5]. VD3 can be antiproliferative in
cells of the skin, colon, breast, and prostate, among others,
and may also limit proinflammatory stresses [6]. Func-
tional vitamin D receptor (VDR) elements have been iden-
tified in the promoter of PTEN, suggesting that vitamin D
may play a role in the regulation of PTEN expression [7].
Moreover, it had been demonstrated that VD3 signifi-
cantly promoted apoptosis in the undifferentiated gastric
cancer cell line HGC-27, which was accompanied by a
concurrent increase in phosphatase and tensin homolog
deletion on chromosome 10 (PTEN) expression with VD3
treatment [8].
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Serum 25-hydroxyvitamin D level is the best indicator
of overall vitamin D status because it reflects total vita-
min D from sunlight exposure, dietary intake, and con-
version from adipose stores in the liver [9-11].
Vitamin D deficiency has long been recognized as a
medical condition characterized by muscle weakness,
ostealgia, and fragility fractures. Vitamin D insufficiency
without overt clinical symptoms has recently become a
concern of physicians and patients [4]. Generally, vitamin
D deficiency refers to a serum level of 25-hydroxyvitamin
D below 50 nmol/L, and vitamin D insufficiency 50 to
75 nmol/L. A number of studies have been done to prove
whether vitamin D has the preventive function to various
kinds of cancers. Results were debatable, and consistent
associations have only been demonstrated in colorectal
cancer [12,13]. The Cohort Consortium Vitamin D Pool-
ing Project of Rarer Cancers have suggested that circulat-
ing 25(OH)D concentration was not significantly
associated with upper GI cancer risk, but analysis on race
subgroup in that study showed that among Asians, lower
concentrations of 25(OH)D were associated with a statis-
tically significant decreased risk of upper GI cancer [14].
A prospective study built an index from factors that pre-
dicted higher vitamin D status were statistically signifi-
cantly associated with a lower risk of esophageal cancer
and non-statistically-significantly with a lower risk of sto-
mach cancer [15]. Another study found that higher
serum 25(OH)D concentrations were associated with
increased risk of esophageal squamous cell carcinoma
(ESCC) in men, but not gastric cardia or noncardia ade-
nocarcinoma [16]. Case-control studies of upper GI can-
cer examining dietary and/or supplemental vitamin D
have reported that higher vitamin D intake is associated
with lower risk of ESCC [17], increased risk of gastric
cancer [18], or had no association with gastric cancer
[19]. However, three studies which used different meth-
ods——more available solar radiation in lower latitudes
[20], higher vitamin D intake [17], and higher vitamin D
exposure index [21]——to estimate vitamin D exposure
unanimously showed higher vitamin D levels were asso-
ciated with lower risk of esophageal or stomach cancer.
Though the relationship between Vitamin D status
and risk of gastric cancer was indeterminate and a pos-
sible relationship has been suggested in many investiga-
tions, it has not been identified whether there is a
definitive correlation between vitamin D status and clin-
icopathologic features of gastric cancer patients. Mean-
while, whether Vitamin D status can predict prognosis
of patients needs further analyis.
Therefore, a retrospective research of the relationship
between serum 25-hydroxyvitamin D and clinicopathologic
characteristics of patients with gastric cancer was per-
formed. Besides, we investigated the prognostic significance




197 gastric carcinoma patients who had been diagnosed by
pathology and received treatment in the cancer center of
Sun Yat-sen University from January 2002 to January 2006
were retrospectively analyzed in this study. Blood from
them was collected after diagnosis and before any kind of
treatment. Subjects who had prior cancer history, daily
vitamin D supplementation or diseases which would affect
serum 25-hydroxyvitamin D were excluded from the
study, including hyperthyroidism, malabsorption, rickets,
osteomalacia, hypercortisolism, serious liver disease
(defined as liver function Child-pugh classification B or
C), renal failure (defined as serum creatinine more than
177 umol/L), and alcoholism. Sera were separated from
the venous blood samples by centrifugation, then ali-
quoted and stored at -80°C until recent use. Clinicopatho-
logic variables and overall survival dates were gained from
medical records. Cancer stage was classified according to
the 7th editions of the UICC TNM staging systems. Writ-
ten informed consent from all subjects and approval from
the independent Institute Research Ethics Committee at
Cancer Center of Sun Yat-sen University were obtained.
Laboratory analysis
Serum 25-hydroxyvitamin D concentrations were
obtained with 25-hydroxy Vitamin D elisa assay (UK
Immunodiagnostic Systems Linited). For assessment of
assay reliability, each plate had double calibrators to
produce standard curve and two control materials. A
total of 197 specimens were measured. The identities of
all sample sources were blind to the laboratory person-
nel. Coefficients of variation for the calibrators, high
control and low control were 2.77%, 6.28% and 12.97%,
respectively.
Statistical analyses
All the statistical analyses were carried out with the
SPSS16.0 statisitical software. P values were derived from
2-sided tests, and those less than 0.05 were considered sta-
tistically significant. One way analysis of variance was used
to analyze the relationship between the serum 25-hydroxy-
vitamin D level and clinicopathological characteristics.
Kaplan-Meier method was used to plot survival curve with
log-rank testing for univariate analysis which included
gender, age, T stage, N stage, M stage, tumor size, tumor
location, Borrmann type, tumor diffirentiation, chemother-
apy, symptom duration(from the time when patient felt
discomfortable to diagnosis), season, BMI(body mass
index), smoking and drinking. The univariables tended to
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be associated with survival (P < 0.05) were chosen to be
analyzed by the Cox proportional hazards model in the
multivariate analysis.
Results
The mean vitamin D level of 197 gastric cancer patients
was 49.85 ± 23.68 nmol/L, ranging from 7.26 to 260.47
nmol/L. None of the results were in the intoxicated
range (≥374 nmol/L) [22]. According to other researches
[23-25], vitamin D levels were divided into three groups:
<50 nmol/L as deficient , 50-75 nmol/L as insufficient,
>75 nmol/L as sufficient. Thus the mean level of sub-
jects in the National Health and Nutrition Examination
Survey fell into insufficient group [26]. The results of
this study were as follows: deficient in 114 patients
(57.9%), insufficient in 67 patients (34%), and sufficient
in 16 patients (8.1%).
The relationship between the serum 25-hydroxyvita-
min D level and clinicopathological characteristics was
showed in Table 1. There were 134 males and 63
females in this study, and the mean Vitamin D levels
were 50.73 ± 18.72 nmol/L in males while 47.96 ± 31.88
nmol/L in females, which showed no significant differ-
ence. It suggested an insignificant tendency (P = 0.073)
that the patients older than 60 years old had higher vita-
min D levels. Vitamin D levels had a significant relation-
ship with the season of blood draw (P = 0.002), when
summer it had the highest levels and winter the lowest
levels. Clinical stage (P = 0.004) and lymph node metas-
tasis classification (P = 0.009) were significantly asso-
ciated with vitamin D levels. Meanwhile, T classification
(P = 0.071) and distant metastasis (P = 0.062) tended to
be insignificantly associated with the vitamin D levels.
However, there was no significant correlation between
the vitamin D levels and tumor size, tumor position,
pathologic differentiation, Borrmann type, symptom
duration, BMI, smoking or drinking.
Among the 197 gastric cancer patients, 106 (53.8%)
died during follow-up of more than 5 years, all of whom
died of cancer recurrence or progress. Kaplan-Meier
survival analysis with log-rank statistics was used to
determine the association between the vitamin D levels
and overall survival. The univariate analysis showed that
the high vitamin D levels group (≥ 50 nmol/L) was asso-
ciated with improved 5-year overall survival compared
with the low vitamin D levels group (< 50 nmol/L).
According to the log-rank test (P = 0.018), there was a
significant difference in overall survival between these
two groups (Figure 1). The 5-year survival rate was
57.8% in high vitamin D levels group and 43% in the
low vitamin D levels group. The mean survival time was
67.3 months and 54.0 months in high and low vitamin
D group respectively.
Kaplan-Meier analysis and the log-rank test were also
used to evaluate the effect of clinicopathological charac-
teristics (Table 2), including gender, age, T classification,
Table 1 Correlation between patient’s clinicopathologic characteristics and vitamin D levels
Variable No.(%) Vitamin D(nmol/l) mean±SD P-value
Gender 0.445
Male 134 (68.0) 50.73 ± 18.72
Female 63 (32.0) 47.96 ± 31.88
Age(years) 0.073
<60 101 (51.3) 46.90 ± 18.24
≥60 96 (48.7) 52.94 ± 28.07
Tumor size(cm) 0.143
<5.0 102 (53.4) 48.12 ± 16.21
≥5.0 89 (46.6) 53.13 ± 29.74
Tumor position 0.462
Cardia/gastric fundus 59 (29.9) 49.36 ± 16.11
Gastric body 50 (25.4) 46.76 ± 17.52
Gastric antrum/pylorus 88 (44.7) 51.93 ± 30.13
Differentiation 0.957
Well/moderate 30 (15.2) 49.63 ± 13.43
Poor 167 (84.8) 49.89 ± 25.11
Borrmann type 0.847
I/II 73 (37.1) 50.27 ± 16.04
III/IV 124 (62.9) 49.60 ± 27.25
Clinical stage 0.004
I/II 75 (38.1) 56.05 ± 29.94
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N classification, distant metastasis, tumor size, tumor
position, Borrmann type, tumor diffirentiation, chemical
therapy, duration from the start of symptom to diagno-
sis, season, BMI(body mass index), smoking and drink-
ing. Results of univariate analysis showed tumor size (P
< 0.001), tumor position (P = 0.011), Borrmann type (P
= 0.001), T classification (P < 0.001), N classification (P
< 0.001), distant metastasis (P < 0.001) and symptom
duration (P = 0.001) were significantly correlated with
survival. The other factors did not have significant rela-
tionship with the survival. The Cox proportional hazards
mode was used to test the independent effects of all the
above significant factors. In this exploratory multivariate
analyses, vitamin D levels (P = 0.019), tumor size (P =
0.026), tumor position (P < 0.001), T classification (P =
0.001), N classification (P = 0.003) and distant metasta-
sis (P < 0.001) were recognized as independent prognos-
tic factors, while Borrmann type (P = 0.135) and
symptom duration (P = 0.067) were not independent
predictors. Therefore, our findings indicate that vitamin
Table 1 Correlation between patient’s clinicopathologic characteristics and vitamin D levels (Continued)
III/IV 122 (61.9) 46.03 ± 17.93
T classification 0.071
T1 17 (8.7) 47.53 ± 10.01
T2 23 (11.8) 56.25 ± 20.07
T3 112 (57.4) 52.07 ± 27.67
T4 43 (22.1) 42.43 ± 15.29
N classification 0.009
N0/N1 76 (40.0) 55.98 ± 29.26
N2/N3 114 (60.0) 46.81 ± 18.63
Distant metastasis 0.062
Positive 29 (14.7) 51.15 ± 24.32
Negative 168 (85.3) 42.28 ± 18.16
Symptom duration(month) 0.494
<4 96 (49.2) 48.82 ± 19.62
≥4 99 (50.8) 51.16 ± 27.19
Season of blood draw 0.002
Spring(Apr-Jun) 36 (18.3) 49.06 ± 34.49
Summer(Jul-Sep) 52 (26.4) 58.68 ± 19.78
Autumn(Oct-Dec) 53 (26.9) 48.86 ± 15.55
Winter(Jan-Mar) 56 (28.4) 39.52 ± 14.68
BMI(kg/m2) 0.458
<25.0 158 (81.0) 50.61 ± 25.12
≥25.0 37 (19.0) 47.39 ± 16.58
Smoking daily 0.818
Yes 73 (37.4) 50.51 ± 20.78
No 122 (62.6) 49.70 ± 25.42
Drinking daily 0.328
Yes 24 (12.3) 45.56 ± 14.18
No 171 (87.7) 50.01 ± 23.74
Figure 1 Comparison of survival rates in patients with high
and low vitamin D levels using Kaplan-Meier curves with
univariate analysis .
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D level has a significant correlation with the prognosis
of gastric cancer.
Discussion
In our study, we first assayed the vitamin D status in
gastric cancer patients, and found out that only 8.1%
patients reached the sufficient level while up to 57.9%
patients were in the deficient level. It has been reported
that vitamin D levels of breast cancer patients were suf-
ficient in 24% patients and deficient in 37.5% [27],
whose overall results were better than that of gastric
cancer. 25-hydroxyvitamin D has been detected in the
healthy Asians and the mean was 59.50 ± 25.25 nmol/L
[28], which was higher than the result 49.85 ± 23.68
nmol/L in our study.
Then we combined the vitamin D level with clinico-
pathological data, which showed that serum 25-hydroxy-
vitamin D concentrations have been inversely associated
with clinical stage and lymph node metastasis. This find-
ing is similar to the results of some clinical studies, in
which serum 25-hydroxyvitamin D concentrations have
been inversely associated with breast cancer stage, for
instance [29,30]. It was found that circulating 25-hydro-
xyvitamin D concentrations were inversely associated
with BMI, as patients with BMI higher than 30 kg/m2
had lower vitamin D levels [23,27]. However, we did not
arrive at this result because in our study patients’ BMI
were seldom higher than 30 kg/m2, so we adjusted the
cutting point at 25 kg/m2. It could be expected that
vitamin D levels of the blood samples drawn in summer
was the highest, as summer offers adequate sunshine,
the major determinant of vitamin D status in humans.
Finally, low vitamin D levels were significantly asso-
ciated with poor survival in univariate analysis. The vita-
min D levels were demonstrated to be an independent
prognostic factor of gastric cancer by the Cox propor-
tional hazards model in the multivariate analysis. In
patients with breast cancer [27], colorectal cancer [31] or
early-stage non-small-cell lung cancer [32], other studies
have also reached the same conclusion that higher 25
Table 2 Univariate and multivariate analysis of different prognostic Variables for overall survival in gastric cancer
patients by Cox regression analysis
Univariate analysis Multivariate analysis
No. of patients P-value Regression coefficient(SE) Hazard ratios(95% confidence internal) P-value
Vitamin D status 0.018 -0.536(0.228) 0.585(0.374-0.914) 0.019
< 50 nmol/L 114
≥ 50 nmol/L 83
Tumor size < 0.001 0.523(0.235) 1.687(1.064-2.673) 0.026
< 5 cm 102
≥ 5 cm 89




Borrmann type 0.001 -0.392(0.262) 0.676(0.404-1.129) 0.135
I/II 73
III/IV 124
T classification <0.001 1.891(0.567) 6.623(2.181-20.115) 0.001
T1/T2 41
T3/T4 154
N classification <0.001 0.859(0.292) 2.362(1.333-4.186) 0.003
N0/N1 76
N2/N3 114
Distant metastasis <0.001 2.374(0.352) 10.739(5.383-21.424) <0.001
Positive 29
Negative 168
Symptom duration 0.001 -0.435(0.238) 0.647(0.406-1.031) 0.067
< 4 months 96
≥ 4 months 99
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OHD levels were associated with better prognosis. We
also found that tumor position was an important prog-
nostic factor, as was explained by the extent of operation
that was required. Patients who underwent subtotal gas-
trectomy had a significantly longer median overall survi-
val than those who underwent a total gastrectomy [33].
Recent findings from Intergroup Trial N9741 revealed
that stage IV colorectal cancer patients randomly
assigned to FOLFOX have improved survival with
higher baseline levels of 25-hydroxyvitamin D [25].
Lower cancer survival rates among black patients may
be due to lower serum 25-hydroxyvitamin D, whose
production from UVB irradiance is lower because of
darker skin [34]. Vitamin D production in the skin
seems to decrease the risk of several solid cancers (espe-
cially stomach, colorectal, liver and gallbladder, pan-
creas, lung, female breast, prostate, bladder and kidney
cancers) [35].
Though the explicit biological mechanisms are not
clear, some data provides a potential explanation for our
findings. VD3 could induce differentiation and cell cycle
arrest in a number of malignant cells, including those in
myeloid leukemia, and breast, prostate, colon, skin and
brain cancer [4,5,36,37]. It has been reported that VD3
(the active form of vitamin D) significantly promoted
apoptosis in the undifferentiated gastric cancer cell line
HGC-27 [8]. Vitamin D may prevent gastric cancers
from progressing by modulating the extracellular micro-
environment, as vitamin D has been shown to alter the
expression of multiple genes in the extracelluar matrix
remodeling [38,39]. VD3 can inhibit Wnt signaling by
interrupting the crosstalk between tumor epithelial cells
and its microenvironment [40]. Functional vitamin D
receptor (VDR) elements have been identified in the
promoter of PTEN, suggesting that vitamin D may play
a role in the regulation of PTEN expression [7]. In
undifferentiated colon cancer cells CYP24A1 (a key
enzyme in vitamin D metabolism) expression was
increased compared with normal cells [41], so it poten-
tially prevented the synthesis of 1,25-dihydroxyvitamin
D3 and restricted its cancer protective effects. What’s
more, vitamin D could also regulate the phenotype of
human breast cancer cells [42].
It was suggested that gastrectomy moderately influ-
enced the metabolism of vitamin D, and vitamin D level
in patients was significantly lower at 1 year or more post-
operatively than at less than 1 year postoperatively, espe-
cially in those who had received total gastrectomy [43].
From the perspective of a gastroenterologist, Vitamin D
supplementation is recommended for persons with disor-
ders of malabsorption and cholestasis [44]. High doses
(1,100 IU) of vitamin D plus calcium were shown to sig-
nificantly reduce cancer incidence in women [45]. From
all the evidence above, perhaps it is reasonable for
vitamin D deficient patients to have appropriate supple-
mentation, however, clinical trials which use high doses
of vitamin D are needed to determine whether vitamin D
really improves survival.
One limitation of our study is that the vitamin D
levels were measured only once at diagnosis, which may
not totally represent the vitamin D levels during cancer
generation or progression. In another study measuring
the serum 25-hydroxyvitamin D concentrations, in
breast cancer patients its correlation coefficient in 1994
and 2008 ranged from 0.42 to 0.52, when measured 12
months respectively it was 0.80 [42], which suggested
the stability of endogenous vitamin D status. The blood
samples of our study were collected once after diagnosis,
before any medical therapy or surgery, so routine life
behavior change was unlikely to affect vitamin D status.
Conclusions
In conclusion, our study provides evidence that serum
vitamin D level is a significant independent prognostic
factor in gastric cancer patients, and vitamin D defi-
ciency may be associated with poor prognosis. We also
describe the correlation between vitamin D level and
clinicopathological characteristics. All the findings
require larger scale prospective studies to confirm. In
addition, the mechanism of potential beneficial effects of
vitamin D in gastric cancer needs further study. Consid-
ering all the existing evidence and the fact that deficient
vitamin D status can be easily corrected by taking sup-
plement or increasing sunlight exposure as well, we cau-
tiously suggest clinicians to evaluate the vitamin D
status of gastric cancer patients, and then consider
appropriate vitamin D supplementation to deficient
patients.
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